Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Genitourinary 2Breast 2Gastrointestinal 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Fanconi Anemia, Complementation Group D1 1

Interventions

emicizumab 4voxelotor 1romiplostim 1recombinant FVIIa 1olaparib 1maltodextrin 1lusutrombopag 1luspatercept 1ibrutinib 1fludarabine phosphate 1continuous erythropoietin receptor activator 1betrixaban 1anti-inhibitor coagulant complex 1Rituximab 1Pharmacogenomic Testing 1Glutamine 1Factor VIII 1Enoxaparin 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × olaparib × Classical hematology × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡